Sun Sheng, Liu Yiyang, Zhou Meiling, Wen Jinyuan, Xue Lin, Han Shenqi, Liang Junnan, Wang Yufei, Wei Yi, Yu Jinjin, Long Xin, Chen Xiaoping, Liang Huifang, Huang Zhao, Zhang Bixiang
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Clinical Medical Research Center of Hepatic Surgery at Hubei Province, Wuhan, China.
Cell Biosci. 2022 May 7;12(1):55. doi: 10.1186/s13578-022-00788-5.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with high mortality. Advanced stage upon diagnosis and cancer metastasis are the main reasons for the dismal prognosis of HCC in large part. The role of proliferation associated protein 2G4 (PA2G4) in tumorigenesis and cancer progression has been widely investigated in various cancers. However, whether and how PA2G4 participates in HCC metastasis is still underexplored.
We found that the mRNA and protein levels of PA2G4 were higher in HCC samples than in normal liver tissues, and high expression of PA2G4 in HCC was correlated with a poor prognosis, by an integrative analysis of immunohistochemistry (IHC), western blot and bioinformatic approach. Moreover, the expression of PA2G4 was elevated in HCC patients with metastases than those metastasis-free. Cell migration, invasion, phalloidin staining and western blot analyses demonstrated that PA2G4 promoted epithelial to mesenchymal transition (EMT) of HCC cells in vitro. And a lung metastasis animal model exhibited that PA2G4 enhanced metastatic ability of HCC cells in vivo. RNA-sequencing combined with dual luciferase reporter assay and evaluation of mRNA half-time indicated that PA2G4 increased FYN expression by stabilizing its mRNA transcript. Recovering the impaired FYN level induced by PA2G4 knockdown rescued the impeded cell mobilities. Furthermore, endogenous immunoprecipitation (IP) and in-situ immunofluorescence (IF) showed that YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) was the endogenous binding patterner of PA2G4. In addition, RNA binding protein immunoprecipitation (RIP) and anti- N6-methyladenosine immunoprecipitation (MeRIP) assays demonstrated that FYN mRNA was N6-methyladenosine (m6A) modified and bound with PA2G4, as well as YTHDF2. Moreover, the m6A catalytic ability of YTHDF2 was found indispensable for the regulation of FYN by PA2G4. At last, the correlation of expression levels between PA2G4 and FYN in HCC tissues was verified by IHC and western blot analysis.
These results indicate that PA2G4 plays a pro-metastatic role by increasing FYN expression through binding with YTHDF2 in HCC. PA2G4 may become a reliable prognostic marker or therapeutic target for HCC patients.
肝细胞癌(HCC)是全球最常见的癌症之一,死亡率很高。诊断时处于晚期以及癌症转移是导致HCC预后不良的主要原因。增殖相关蛋白2G4(PA2G4)在各种癌症的肿瘤发生和癌症进展中的作用已得到广泛研究。然而,PA2G4是否以及如何参与HCC转移仍未得到充分探索。
通过免疫组织化学(IHC)、蛋白质印迹和生物信息学方法的综合分析,我们发现HCC样本中PA2G4的mRNA和蛋白质水平高于正常肝组织,且HCC中PA2G4的高表达与不良预后相关。此外,与无转移的HCC患者相比,发生转移的HCC患者中PA2G4的表达升高。细胞迁移、侵袭、鬼笔环肽染色和蛋白质印迹分析表明,PA2G4在体外促进HCC细胞的上皮-间质转化(EMT)。并且一个肺转移动物模型显示,PA2G4在体内增强了HCC细胞的转移能力。RNA测序结合双荧光素酶报告基因检测以及mRNA半衰期评估表明,PA2G4通过稳定其mRNA转录本增加FYN表达。恢复由PA2G4敲低诱导的受损FYN水平挽救了受阻的细胞迁移能力。此外,内源性免疫沉淀(IP)和原位免疫荧光(IF)显示,YTH N6-甲基腺苷RNA结合蛋白2(YTHDF2)是PA2G4的内源性结合模式分子。另外,RNA结合蛋白免疫沉淀(RIP)和抗N6-甲基腺苷免疫沉淀(MeRIP)检测表明,FYN mRNA被N6-甲基腺苷(m6A)修饰并与PA2G4以及YTHDF2结合。此外,发现YTHDF2的m6A催化能力对于PA2G4对FYN的调节不可或缺。最后,通过IHC和蛋白质印迹分析验证了HCC组织中PA2G4和FYN表达水平之间的相关性。
这些结果表明,在HCC中,PA2G4通过与YTHDF2结合增加FYN表达发挥促转移作用。PA2G4可能成为HCC患者可靠的预后标志物或治疗靶点。